 |
424 Diseases |  |
807 Trials |
|
807 Trials |  |
14372 News |  |
| «12...224225226227228229230231232233234235236» |
- Rituxan (rituximab) / Roche
Enrollment change: Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Leukemia (clinicaltrials.gov) - Jan 24, 2012
P2, N=21, Completed, Sponsor: Sidney Kimmel Comprehensive Cancer Center
N=30 --> 21
- |||||||||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
New P2/3 trial, Surgery, Metastases: PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery (clinicaltrials.gov) - Jan 22, 2012
P2/3, N=1060, Recruiting, Sponsor: North Central Cancer Treatment Group
- | Avastin (bevacizumab) / Roche
New P2 trial, Metastases: Study of Vitamin D in Untreated Metastatic Colorectal Cancer (clinicaltrials.gov) - Jan 22, 2012
P2, N=120, Recruiting, Sponsor: Dana-Farber Cancer Institute
- | mitomycin / Generic mfg.
Enrollment closed, Surgery, Metastases: Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer (clinicaltrials.gov) - Jan 22, 2012
P3, N=340, Active, not recruiting, Sponsor: Walter Reed Army Medical Center
N=30 --> 21 Recruiting --> Active, not recruiting
- ||| Avastin (bevacizumab) / Roche
Trial completion, Metastases: Study of CGC-11047 When Used in Individual Combinations With 1) Gemcitabine or 2) Docetaxel or 3) Bevacizumab or 4) Erlotinib or 5) Cisplatin or 6) 5-Flurouracil or 7) Sunitinib in Patients With Advanced Solid Tumors or Lymphoma (clinicaltrials.gov) - Jan 21, 2012
P1, N=172, Completed, Sponsor: Progen Pharmaceuticals
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | Avastin (bevacizumab) / Roche
Trial initiation date, Metastases: GFL: Study of Gamma Interfereon in Metastatic Colorectal Carcinoma (clinicaltrials.gov) - Jan 17, 2012
P2, N=48, Completed, Sponsor: Accelerated Community Oncology Research Network
Active, not recruiting --> Completed Initiation date: Apr 2003 --> Feb 2006
- | Avastin (bevacizumab) / Roche
Enrollment change, Metastases: GFL: Study of Gamma Interfereon in Metastatic Colorectal Carcinoma (clinicaltrials.gov) - Jan 17, 2012
P2, N=48, Completed, Sponsor: Accelerated Community Oncology Research Network
Initiation date: Apr 2003 --> Feb 2006 N=70 --> 48
- |||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Trial completion: Study of 5-FU + Leucovorin + CPT-11 in Patients With Resectable Liver Metastases From Colorectal Adenocarcinoma (clinicaltrials.gov) - Jan 17, 2012
P2, N=70, Completed, Sponsor: AHS Cancer Control Alberta
N=70 --> 48 Active, not recruiting --> Completed
- |||| Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Trial completion, Metastases: Study of S-1 Plus LV for Untreated Metastatic Colorectal Cancer (clinicaltrials.gov) - Jan 16, 2012
P2, N=73, Completed, Sponsor: Taiho Pharmaceutical Co., Ltd.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Avastin (bevacizumab) / Roche
Trial completion, Metastases: Study of Docetaxel, Cisplatin, and Fluorouracil (Modified DCF) With Bevacizumab in Patients With Unresectable or Metastatic Gastroesophageal Adenocarcinoma (clinicaltrials.gov) - Jan 16, 2012
P2, N=46, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Angiocept (pegdinetanib) / BMS
Enrollment change, Combination therapy, Metastases: Ph II Trial of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Second-line Treatment of Metastatic Colorectal Cancer (clinicaltrials.gov) - Jan 12, 2012
P2, N=17, Completed, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Completed N=116 --> 17
- | Angiocept (pegdinetanib) / BMS
Trial completion, Combination therapy, Metastases: Ph II Trial of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Second-line Treatment of Metastatic Colorectal Cancer (clinicaltrials.gov) - Jan 12, 2012
P2, N=17, Completed, Sponsor: Bristol-Myers Squibb
N=116 --> 17 Active, not recruiting --> Completed
- thioguanine / Generic mfg.
Trial completion: SWOG-9400 Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Previously Untreated Acute Lymphocytic Leukemia (clinicaltrials.gov) - Jan 12, 2012
P2, N=50, Completed, Sponsor: Southwest Oncology Group
Active, not recruiting --> Completed Active, not recruiting --> Completed
- zidovudine / Generic mfg., trimethoprim/sulfamethoxazole / Generic mfg.
Trial completion: SWOG 9320: SWOG-9320 Combination Chemotherapy, Radiation Therapy, and Antiviral Therapy in Treating Patients With AIDS-Related Lymphoma (clinicaltrials.gov) - Jan 11, 2012
P2, N=52, Completed, Sponsor: Southwest Oncology Group
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion: Phase III Trial of DP Followed by FOLFIRI or the Reverse Sequence in Unresectable Gastric Cancer (clinicaltrials.gov) - Jan 10, 2012
P3, N=200, Completed, Sponsor: Samsung Medical Center
Active, not recruiting --> Completed Terminated --> Completed
- | Avastin (bevacizumab) / Roche, Vectibix (panitumumab) / Amgen
New P2 trial: BOS2: Efficacy of FOLFOX Alone, FOLFOX Plus Bevacizumab and FOLFOX Plus Panitumumab in Patients With Resectable Liver Metastases (clinicaltrials.gov) - Jan 8, 2012
P2, N=360, Recruiting, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
- ||| E7820 / Eisai
Trial initiation date, Metastases: Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer (clinicaltrials.gov) - Jan 5, 2012
P1/2, N=95, Active, not recruiting, Sponsor: Eisai Inc.
Terminated --> Completed Initiation date: Apr 2011 --> Oct 2011
- Trial initiation date: POWERRANGER: Preoperative Chemotherapy vs. Chemoradiation in Esophageal / GEJ Adenocarcinoma (clinicaltrials.gov) - Jan 4, 2012
P2/3, N=12, Recruiting, Sponsor: Gordon Buduhan
Initiation date: Apr 2011 --> Oct 2011 Initiation date: Sep 2011 --> Dec 2011
- Enrollment open: POWERRANGER: Preoperative Chemotherapy vs. Chemoradiation in Esophageal / GEJ Adenocarcinoma (clinicaltrials.gov) - Jan 4, 2012
P2/3, N=12, Recruiting, Sponsor: Gordon Buduhan
Initiation date: Sep 2011 --> Dec 2011 Not yet recruiting --> Recruiting
- | Removab (catumaxomab) / NeoPharm, Trion Pharma
New P2 trial: Catumaxomab for Treatment of Peritoneal Carcinomatosis in Patients With Gastric Adenocarcinomas (clinicaltrials.gov) - Jan 3, 2012
P2, N=42, Recruiting, Sponsor: AIO-Studien-gGmbH
- | pazopanib / Generic mfg.
New P2 trial, Metastases: PaFLO: FLO +/- Pazopanib as First-line Treatment in Advanced Gastric Cancer (clinicaltrials.gov) - Dec 21, 2011
P2, N=75, Recruiting, Sponsor: Charite University, Berlin, Germany
- | New P2 trial, Metastases: S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer (clinicaltrials.gov) - Dec 21, 2011
P2, N=225, Recruiting, Sponsor: Southwest Oncology Group
- Odomzo (sonidegib) / Sun Pharma
Enrollment open, Combination therapy, Metastases: LDE225 With Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan for Untreated Advanced Pancreatic Cancer (clinicaltrials.gov) - Dec 20, 2011
P1, N=40, Recruiting, Sponsor: Massachusetts General Hospital
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||||||| Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
New P3 trial, Metastases: NAPOLI-1: Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer (clinicaltrials.gov) - Dec 15, 2011
P3, N=405, Active, not recruiting, Sponsor: Merrimack Pharmaceuticals
- ||| Cyramza (ramucirumab) / Eli Lilly, icrucumab (IMC-18F1) / Eli Lilly
Trial initiation date, Combination therapy, Metastases: A Study of Ramucirumab or Icrucumab in Colorectal Cancer (clinicaltrials.gov) - Dec 14, 2011
P2, N=156, Active, not recruiting, Sponsor: ImClone LLC
Not yet recruiting --> Recruiting Initiation date: Apr 2010 --> Aug 2010
- demcizumab (OMP-21M18) / Mereo Biopharma, BMS
Enrollment closed, IO biomarker, Metastases: A Study of FOLFIRI Plus OMP-21M18 as 1st or 2nd-line Treatment in Subjects With Metastatic Colorectal Cancer (clinicaltrials.gov) - Dec 14, 2011
P1, N=32, Active, not recruiting, Sponsor: OncoMed Pharmaceuticals, Inc.
Initiation date: Apr 2010 --> Aug 2010 Recruiting --> Active, not recruiting
- ||| Vectibix (panitumumab) / Amgen
Enrollment closed: PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors (clinicaltrials.gov) - Dec 14, 2011
P2, N=285, Active, not recruiting, Sponsor: Amgen
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- oxaliplatin / Generic mfg.
Trial completion: Hyperthermic Intraperitoneal Oxaliplatin for Peritoneal Malignancies (clinicaltrials.gov) - Dec 14, 2011
P1, N=17, Completed, Sponsor: Masonic Cancer Center, University of Minnesota
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg.
Trial completion, Metastases: A Single Arm Trial of Oxaliplatin and 5FU With Concurrent Radiation in Patients With Metastatic Rectal Cancer (clinicaltrials.gov) - Dec 13, 2011
P2, N=26, Completed, Sponsor: Peter MacCallum Cancer Centre, Australia
Active, not recruiting --> Completed Recruiting --> Completed
- | New P2 trial, Metastases: Phase II Study of FOLFOXIRI in Patients With Locally Advanced or Metastatic Biliary Tract Cancer (clinicaltrials.gov) - Dec 12, 2011
P2, N=53, Recruiting, Sponsor: Soon Chun Hyang University
- ||||| Inlyta (axitinib) / Pfizer
New P2 trial, Metastases: A Trial of Single Agent Axitinib as Maintenance Therapy for Patients With First Line Metastatic Colorectal Cancer (mCRC) (clinicaltrials.gov) - Dec 11, 2011
P2, N=69, Active, not recruiting, Sponsor: SCRI Development Innovations, LLC
- oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg., floxuridine / Generic mfg.
Enrollment change: Isolated Liver Perfusion With Oxaliplatin (clinicaltrials.gov) - Dec 7, 2011
P1, N=10, Completed, Sponsor: University of Pittsburgh
Recruiting --> Completed N=30 --> 10
- oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg., floxuridine / Generic mfg.
Trial completion: Isolated Liver Perfusion With Oxaliplatin (clinicaltrials.gov) - Dec 7, 2011
P1, N=10, Completed, Sponsor: University of Pittsburgh
N=30 --> 10 Active, not recruiting --> Completed
- | New P2 trial, Metastases: Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer (clinicaltrials.gov) - Dec 6, 2011
P2, N=61, Recruiting, Sponsor: Pancreatic Cancer Research Team
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
New P1/2 trial: CUFOX: Combining Curcumin With FOLFOX Chemotherapy in Patients With Inoperable Colorectal Cancer (clinicaltrials.gov) - Dec 6, 2011
P1/2, N=51, Not yet recruiting, Sponsor: University of Leicester
- dalotuzumab (MK 0646) / Merck (MSD), Pierre Fabre, Avastin (bevacizumab) / Roche
Enrollment change, Metastases: FOLFOX/Bevacizumab +/- MK-0646 in Metastatic Colorectal Cancer (clinicaltrials.gov) - Dec 1, 2011
P2, N=0, Withdrawn, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Active, not recruiting --> Completed N=160 --> 0
- Odomzo (sonidegib) / Sun Pharma
New P1 trial, Combination therapy, Metastases: LDE225 With Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan for Untreated Advanced Pancreatic Cancer (clinicaltrials.gov) - Nov 30, 2011
P1, N=40, Recruiting, Sponsor: Massachusetts General Hospital
- | Arzerra (ofatumumab) / Novartis, Genmab, Rituxan (rituximab) / Roche
New P2 trial: Ofatumumab With IVAC Salvage Chemotherapy in Diffuse Large B Cell Lymphoma Patients (clinicaltrials.gov) - Nov 27, 2011
P2, N=77, Recruiting, Sponsor: Polish Lymphoma Research Group
- Trial termination: A Study of Pre-Operative Treatment of Newly-Diagnosed, Surgically-Resectable Osteosarcoma With Doxorubicin, Ifosfamide, Etoposide, and Cisplatin With Early Metabolic Assessment of Response (clinicaltrials.gov) - Nov 22, 2011
P1, N=2, Terminated, Sponsor: University of Chicago
N=160 --> 0 Recruiting --> Terminated; PI no longer affiliated with institution; only 2 subjects enrolled
- Enrollment change: A Study of Pre-Operative Treatment of Newly-Diagnosed, Surgically-Resectable Osteosarcoma With Doxorubicin, Ifosfamide, Etoposide, and Cisplatin With Early Metabolic Assessment of Response (clinicaltrials.gov) - Nov 22, 2011
P1, N=2, Terminated, Sponsor: University of Chicago
Recruiting --> Terminated; PI no longer affiliated with institution; only 2 subjects enrolled N=15 --> 2
- ||||| simtuzumab (GS 6624) / Gilead
New P2 trial, Metastases: Efficacy and Safety of Simtuzumab (SIM) With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma (clinicaltrials.gov) - Nov 22, 2011
P2, N=265, Active, not recruiting, Sponsor: Gilead Sciences
- ||||| Fotivda (tivozanib) / Kyowa Kirin, LG Chem
New P2 trial, Combination therapy, Metastases: A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy (clinicaltrials.gov) - Nov 21, 2011
P2, N=265, Active, not recruiting, Sponsor: Astellas Pharma Inc
- Rituxan (rituximab) / Roche
Enrollment open: S1106 Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell Lymphoma (clinicaltrials.gov) - Nov 20, 2011
P2, N=180, Recruiting, Sponsor: Southwest Oncology Group
N=15 --> 2 Not yet recruiting --> Recruiting
- ganitumab (AMG 479) / Takeda, ImmunityBio
New P2 trial, Metastases: Combination Chemotherapy With or Without Ganitumab in Treating Patients With Previously Untreated Metastatic Pancreatic Cancer (clinicaltrials.gov) - Nov 15, 2011
P2, N=0, Withdrawn, Sponsor: Cancer and Leukemia Group B
- ||||| Herceptin (trastuzumab) / Roche
New P2 trial: HerFLOT: Explorative Phase II Study of Perioperative Treatment in Patients With Adenocarcinoma of the Gastroesophageal Junction or Stomach (clinicaltrials.gov) - Nov 14, 2011
P2, N=53, Active, not recruiting, Sponsor: AIO-Studien-gGmbH
- ||| telisotuzumab (h224G11) / AbbVie
New P1 trial, Metastases: Study of ABT-700 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Nov 14, 2011
P1, N=124, Recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
- | Cyramza (ramucirumab) / Eli Lilly
Trial completion, Combination therapy, Metastases: A Study of IMC-1121B (Ramucirumab) in Colorectal Cancer (clinicaltrials.gov) - Nov 14, 2011
P2, N=48, Completed, Sponsor: Eli Lilly and Company
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | adecatumumab (MT201) / Amgen
Enrollment change: Study of Adecatumumab Relative to FOLFOX After R0 Resection of Colorectal Liver Metastases (clinicaltrials.gov) - Nov 9, 2011
P2, N=35, Completed, Sponsor: Amgen Research (Munich) GmbH
Active, not recruiting --> Completed N=90 --> 35
- | adecatumumab (MT201) / Amgen
Trial completion: Study of Adecatumumab Relative to FOLFOX After R0 Resection of Colorectal Liver Metastases (clinicaltrials.gov) - Nov 9, 2011
P2, N=35, Completed, Sponsor: Amgen Research (Munich) GmbH
N=90 --> 35 Active, not recruiting --> Completed
- | 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
New P4 trial, Metastases: Study Comparing Optimized 5-FU Dosing and Standard Dosing in Metastatic Colorectal Cancer Patients Treated With mFOLFOX6 (clinicaltrials.gov) - Nov 7, 2011
P4, N=51, Terminated, Sponsor: Myriad Genetic Laboratories, Inc.